ROS Therapeutics ApS — Credit Rating and Financial Key Figures
CVR number: 39507501
Veddelev Engvej 6, Veddelev 4000 Roskilde
Income statement (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -2 139.83 | -2 037.63 | -4 763.31 | -3 096.33 | - 677.65 |
| Employee benefit expenses | - 203.56 | - 150.57 | - 604.72 | - 615.72 | -12.71 |
| EBIT | -2 343.39 | -2 188.20 | -5 368.03 | -3 712.06 | - 690.35 |
| Other financial income | 3.96 | 0.23 | 39.13 | 8.72 | 25.56 |
| Other financial expenses | -20.33 | - 114.93 | - 393.94 | - 381.18 | - 563.44 |
| Pre-tax profit | -2 359.75 | -2 302.91 | -5 722.83 | -4 084.52 | -1 228.22 |
| Income taxes | 475.68 | 402.55 | 1 341.34 | 734.14 | 75.83 |
| Net earnings | -1 884.07 | -1 900.36 | -4 381.49 | -3 350.37 | -1 152.39 |
Assets (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Non-current loans receivable | 0.73 | 0.73 | |||
| Long term receivables total | 0.73 | 0.73 | |||
| Inventories total | |||||
| Current amounts owed by group member comp. | 3 999.92 | 100.00 | 105.00 | 110.25 | |
| Prepayments and accrued income | 0.81 | 12.36 | 6.49 | 44.18 | |
| Current other receivables | 11.10 | 25.11 | 15.12 | 14.94 | 14.75 |
| Current deferred tax assets | 475.68 | 402.55 | 1 122.92 | 734.14 | 75.83 |
| Short term receivables total | 4 487.50 | 427.66 | 1 250.40 | 860.57 | 245.01 |
| Other current investments | 0.73 | ||||
| Cash and bank deposits | 608.46 | 9 748.66 | 5 036.28 | 2 511.25 | 1 661.65 |
| Cash and cash equivalents | 608.46 | 9 748.66 | 5 037.02 | 2 511.25 | 1 661.65 |
| Balance sheet total (assets) | 5 095.97 | 10 176.32 | 6 287.42 | 3 372.56 | 1 907.39 |
Equity and liabilities (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 81.56 | 148.30 | 148.30 | 148.30 | 148.30 |
| Share premium account | 4 433.40 | 4 433.40 | 4 433.40 | 4 433.40 | |
| Shares repurchased | 4 000.00 | ||||
| Retained earnings | 2 826.18 | 942.11 | - 958.25 | -5 339.75 | -8 690.12 |
| Profit of the financial year | -1 884.07 | -1 900.36 | -4 381.49 | -3 350.37 | -1 152.39 |
| Shareholders equity total | 5 023.67 | 3 623.46 | - 758.04 | -4 108.41 | -5 260.81 |
| Non-current loans from credit institutions | 5 915.15 | 6 132.37 | 6 431.87 | 6 941.33 | |
| Non-current liabilities total | 5 915.15 | 6 132.37 | 6 431.87 | 6 941.33 | |
| Current trade creditors | 72.29 | 557.57 | 887.53 | 1 034.93 | 226.77 |
| Other non-interest bearing current liabilities | 80.14 | 25.56 | 14.17 | 0.10 | |
| Current liabilities total | 72.29 | 637.72 | 913.09 | 1 049.10 | 226.87 |
| Balance sheet total (liabilities) | 5 095.97 | 10 176.32 | 6 287.42 | 3 372.56 | 1 907.39 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.